Results 131 to 140 of about 3,260 (169)

The pharmacology and clinical application of thrombopoietin receptor agonists

International Journal of Hematology, 2014
The discovery and application of thrombopoietin (TPO) and thrombopoietin receptor (TPOR) agonists have changed the clinical treatment of thrombocytopenia. These compounds exert favorable clinical effects without the adverse events caused by traditional treatments (e.g., corticosteroids, immunoglobulins, monoclonal antibodies and splenectomy).
Caizheng, Li, Li, Zheng
openaire   +2 more sources

Eltrombopag: A Novel Oral Thrombopoietin Receptor Agonist

Annals of Pharmacotherapy, 2010
To review the pharmacology and pharmacokinetics and evaluate the safety and efficacy of eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) and thrombocytopenia associated with hepatitis C virus (HCV) cirrhosis.A Cochrane Controlled Trial Register, clinicaltrials.gov, EMBASE, and MEDLINE search was performed ...
Shelby L, Corman, Rima A, Mohammad
openaire   +2 more sources

Thrombopoietin receptor agonists in the treatment of thrombocytopenia

Current Opinion in Hematology, 2009
The basis of treatment for immune thrombocytopenic purpura (ITP) has conventionally relied on nonspecific immune suppression designed to reduce platelet destruction. As a consequence, at least half of the morbidity and mortality in this condition is related to infection secondary to treatment, and alternative treatments are desirable.It has been shown ...
openaire   +2 more sources

New thrombopoietin receptor agonists for platelet disorders

Drugs of Today, 2012
Since thrombopoietin (TPO) was cloned in 1994, TPO receptor (TPO-R) agonists have been developed which have shown significant clinical activity in various conditions characterized by thrombocytopenia. First-generation TPO-R agonists were recombinant forms of human TPO.
S, Homeida, C, Ebdon, P, Batty, B, Jackson, S, Kolade, C, Bateman, Y Y, Peng, R, Stasi   +7 more
openaire   +2 more sources

Thrombopoietin Receptor Agonists

2017
Thrombopoietin receptor agonists (TPO-RAs) should be considered for the treatment of “refractory” autoimmune thrombocytopenia (ITP). In contrast to other medications, TPO-RAs increase platelets via stimulating the production of megakaryocytes/platelets in the bone marrow. This chapter has dealt with the mechanism, efficacy, and safety of TPO-RAs.
openaire   +1 more source

Pyrimidine benzamide-based thrombopoietin receptor agonists

Bioorganic & Medicinal Chemistry Letters, 2007
A series of pyrimidine benzamide-based thrombopoietin receptor agonists is described. The lead molecule contains a 2-amino-5-unsubstituted thiazole, a group that has been associated with idiosyncratic toxicity. The potential for metabolic oxidation at C-5 of the thiazole, the likely source of toxic metabolites, was removed by substitution at C-5 or by ...
Lawrence A, Reiter, Chakrapani, Subramanyam, Emilio J, Mangual, Christopher S, Jones, Marc I, Smeets, William H, Brissette, Sandra P, McCurdy, Paul D, Lira, Robert G, Linde, Qifang, Li, Fangning, Zhang, Amy S, Antipas, Laura C, Blumberg, Jonathan L, Doty, James P, Driscoll, Michael J, Munchhof, Sharon L, Ripp, Andrei, Shavnya, Richard M, Shepard, Diana, Sperger, Lisa M, Thomasco, Kristen A, Trevena, Lilli A, Wolf-Gouveia, Liling, Zhang   +23 more
openaire   +2 more sources

Mechanisms and therapeutic prospects of thrombopoietin receptor agonists

Seminars in Hematology, 2019
The second-generation thrombopoietin (TPO) receptor agonists eltrombopag and romiplostim are potent activators of megakaryopoiesis and represent a growing treatment option for patients with thrombocytopenic hematological disorders. Both TPO receptor agonists have been approved worldwide for the treatment of children and adults with chronic immune ...
James Bussel, Austin Kulasekararaj, Nichola Cooper, Amit Verma, Ulrich Steidl, John W. Semple, Britta Will   +6 more
openaire   +2 more sources

Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia

Hämostaseologie, 2019
AbstractManagement of patients with corticosteroid-refractory immune thrombocytopaenia (ITP) possesses a significant challenge to practitioners. Until recently, options included splenectomy and immunosuppression. With improved knowledge of both thrombopoiesis and the pathophysiology of ITP, novel drug development with thrombopoietin-receptor agonists ...
openaire   +2 more sources

Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease

Seminars in Thrombosis and Hemostasis, 2020
AbstractThrombocytopenia is one of the most common hematologic complications in cirrhosis. Despite limited data linking platelet count and bleeding risk in patients with cirrhosis, the use of platelets transfusions for invasive procedures has been a common practice. Recently, thrombopoietin (TPO) receptor agonists have been approved for use in patients
Saro, Khemichian, Norah A, Terrault
openaire   +2 more sources

Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics

Hämostaseologie
AbstractThis review summarizes the rationale and current data on the use of thrombopoietin receptor agonists (TPO-RAs) for treating severe thrombocytopenia in infants, children, and adolescents. It focuses on substances that have been approved by the U.S.
Jennifer, Gebetsberger, Werner, Streif, Christof, Dame   +2 more
openaire   +2 more sources